Company Description
Eleison Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to acquiring, developing and commercializing late-stage therapies (in Phase II or Phase III trials) to treat rare, life-threatening diseases, such as pancreatic cancer, small cell lung cancer, pediatric bone cancer and brain cancer.
Our current portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD).
Each has received Orphan Drug Designation by the FDA, and glufosfamide and ILC have received Orphan Drug Designation by the EMA as well.
Each of the oncology indications we have targeted are characterized by significant unmet medical needs, that is, indications with a poor prognosis and low five year survival.
Our lead program, glufosfamide, is in development for pancreatic cancer, the third leading cause of cancer deaths in the United States according to the American Cancer Society.
Our ongoing pivotal Phase III study for glufosfamide in second-line pancreatic cancer is expected to be completed in 2023 with an NDA filing, with the FDA projected for 2024.
| Country | United States |
| Founded | 2009 |
| Industry | Health Care |
| Sector | Biotechnology |
| Employees | 2 |
| CEO | Edwin J. Thomas |
Contact Details
Address: 100 Overlook Center, 2nd Floor Princeton, NJ 08540 United States | |
| Phone | (215) 554-3530 |
| Website | eleison-pharma.com |
Stock Details
| Ticker Symbol | ELSN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001880047 |
| Employer ID | 45-4373885 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Edwin J. Thomas | Chief Executive Officer, President and Chairman of the Board |
| Keith Darragh, CPA, CGMA | Chief Financial Officer and Secretary |
| Michael E. Lusty | Vice President – Chemistry Manufacture and Contracts |
| Patrick Maguire, MD, PhD | Chief Medical Officer |
| Matthew Allen Cromie | Vice President – Clinical Research |
| Joel Morganroth, MD | Director |
| Michael J. Otto, PhD | Director |
| Frank Seidman | Director |
| Bryan R. Wood | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 29, 2023 | RW | Filing |
| Sep 19, 2022 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Sep 14, 2022 | D | Notice of Exempt Offering of Securities |
| Feb 23, 2022 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 24, 2022 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 13, 2021 | DRS | [Cover] Draft Registration Statement |